Raiffeisen Bank International AG Invests $1.13 Million in CRISPR Therapeutics AG $CRSP

Raiffeisen Bank International AG acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 2nd quarter, Holdings Channel reports. The firm acquired 20,000 shares of the company’s stock, valued at approximately $1,127,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CRSP. Versant Capital Management Inc raised its stake in CRISPR Therapeutics by 175.1% in the second quarter. Versant Capital Management Inc now owns 465 shares of the company’s stock valued at $25,000 after purchasing an additional 296 shares in the last quarter. Mcguire Capital Advisors Inc. acquired a new position in shares of CRISPR Therapeutics during the fourth quarter worth $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics in the 4th quarter valued at $26,000. Rothschild Investment LLC boosted its holdings in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares in the last quarter. Finally, Strategic Wealth Investment Group LLC acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at $36,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $55.79 on Friday. The company has a market capitalization of $5.39 billion, a PE ratio of -11.72 and a beta of 1.76. The company has a quick ratio of 17.85, a current ratio of 17.85 and a debt-to-equity ratio of 0.34. The firm has a fifty day simple moving average of $53.86 and a 200 day simple moving average of $52.95. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The business had revenue of $10.18 million for the quarter. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -4.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CRSP shares. Sanford C. Bernstein boosted their price objective on CRISPR Therapeutics from $50.00 to $56.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price target on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, August 31st. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday, August 25th. Finally, HC Wainwright reiterated a “buy” rating on shares of CRISPR Therapeutics in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $68.06.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.